Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL
NCT07671378Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, sonrotoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Jiangsu Provincial People's Hospital. Started Jun 2026; status: recruiting.
02
Drugs
zanubrutinibsonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07671378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671378.